Chromodomain Helicase DNA Binding Protein 1-like, a negative regulator of Forkhead box O3a, promotes the proliferation and migration of Angiotensin II-induced vascular smooth muscle cells

References

• Gamil S, Erdmann J, Schwedhelm E, et al. Increased serum levels of asymmetric dimethylarginine and symmetric dimethylarginine and decreased levels of arginine in Sudanese patients with essential hypertension. Kidney Blood Press Res. 2020;45(5):727–736.
   PubMed Web of Science ®Google Scholar
• Butchart A, Mikton C, Dahlberg LL, et al. Global status report on violence prevention 2014. Inj Prev. 2015 Jun;21(3):213.
   PubMed Web of Science ®Google Scholar
• Campbell NR, Lackland DT, Lisheng L, et al. Using the global burden of disease study to assist development of nation-specific fact sheets to promote prevention and control of hypertension and reduction in dietary salt: a resource from the world hypertension league. J Clin Hypertens (Greenwich, CT). 2015 Mar;17(3):165–167.
   PubMed Web of Science ®Google Scholar
• Arif M, Sadayappan S, Becker RC, et al. Epigenetic modification: a regulatory mechanism in essential hypertension. Hypertens Res. 2019 Aug;42(8):1099–1113.
   PubMed Web of Science ®Google Scholar
• Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med. 2011 Nov 7;17(11):1402–1409.
   PubMed Web of Science ®Google Scholar
• Parati G, Ochoa JE, Lombardi C, et al. Assessment and management of blood-pressure variability. Nat Rev Cardiol. 2013 Mar;10(3):143–155.
   PubMed Web of Science ®Google Scholar
• Grootaert MOJ, Moulis M, Roth L, et al. Vascular smooth muscle cell death, autophagy and senescence in atherosclerosis. Cardiovasc Res. 2018 Mar 15;114(4):622–634.
   PubMed Web of Science ®Google Scholar
• Touyz RM, Alves-Lopes R, Rios FJ, et al. Vascular smooth muscle contraction in hypertension. Cardiovasc Res. 2018 Mar 15;114(4):529–539.
   PubMed Web of Science ®Google Scholar
• Shi J, Yang Y, Cheng A, et al. Metabolism of vascular smooth muscle cells in vascular diseases. Am J Physiol Heart Circ Physiol. 2020 Sep 1;319(3):H613–h631.
   PubMed Web of Science ®Google Scholar
• Montezano AC, Nguyen Dinh Cat A, Rios FJ, et al. Angiotensin II and vascular injury. Curr Hypertens Rep. 2014 Jun;16(6):431.
   PubMed Web of Science ®Google Scholar
• Xiang R, Chen J, Li S, et al. VSMC-specific deletion of FAM3A attenuated Ang II-promoted hypertension and cardiovascular hypertrophy. Circ Res. 2020 Jun 5;126(12):1746–1759.
   PubMed Web of Science ®Google Scholar
• Ma NF, Hu L, Fung JM, et al. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology. 2008 Feb;47(2):503–510.
   PubMed Web of Science ®Google Scholar
• Cheng W, Su Y, Xu F. CHD1L: a novel oncogene. Mol Cancer. 2013 Dec 21;12(1):170.
   PubMedGoogle Scholar
• Wang W, Wu J, Fei X, et al. CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer. Am J Transl Res. 2019;11(3):1581–1592.
   PubMed Web of Science ®Google Scholar
• Li Y, He LR, Gao Y, et al. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer. Cell Death Dis. 2019 Feb 4;10(2):99.
   PubMedGoogle Scholar
• Sun J, Zhang L, Zhao H, et al. CHD1L regulates cell cycle, apoptosis, and migration in glioma. Cell Mol Neurobiol. 2016 May;36(4):565–576.
   PubMed Web of Science ®Google Scholar
• Zhang X, Bai Y, Huang L, et al. CHD1L augments autophagy-mediated migration of hepatocellular carcinoma through targeting ZKSCAN3. Cell Death Dis. 2021 Oct 15;12(10):950.
   PubMed Web of Science ®Google Scholar
• Li S, Chai Y, Ding Y, et al. CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma. Oncol Rep. 2019 Aug;42(2):657–669.
   PubMed Web of Science ®Google Scholar
• Chung HW, Lim JH, Kim MY, et al. High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway. Nephrol Dialysis Trans. 2012 Jun;27(6):2213–2225.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang M, Zhou T, et al. Exendin-4 promotes the vascular smooth muscle cell re-differentiation through AMPK/SIRT1/FOXO3a signaling pathways. Atherosclerosis. 2018 Sep;276:58–66.
   PubMed Web of Science ®Google Scholar
• Liu DF, Li SM, Zhu QX, et al. The involvement of miR-155 in blood pressure regulation in pregnant hypertension rat via targeting FOXO3a. Eur Rev Med Pharmacol Sci. 2018 Oct;22(20):6591–6598.
   PubMed Web of Science ®Google Scholar
• Wei Z, Yang Y, Li Q, et al. The transcriptome of circulating cells indicates potential biomarkers and therapeutic targets in the course of hypertension-related myocardial infarction. Genes Dis. 2021 Jul;8(4):555–568.
   PubMed Web of Science ®Google Scholar
• Fornes O, Castro-Mondragon JA, Khan A, et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2020 Jan 8;48(D1):D87–d92.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu B, Zhu J, et al. Nicotine-mediated autophagy of vascular smooth muscle cell accelerates atherosclerosis via nAChRs/ROS/NF-κB signaling pathway. Atherosclerosis. 2019 May;284:1–10.
   PubMed Web of Science ®Google Scholar
• Zhong X, Xiu H, Bi Y, et al. Targeting eIF5A2 inhibits prostate carcinogenesis, migration, invasion and metastasis in vitro and in vivo. Bioengineered. 2020 Jan 1;11(1):619–627.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, Calif). 2001 Dec;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Wang S, Li P, Jiang G, et al. Long non-coding RNA LOC285194 inhibits proliferation and migration but promoted apoptosis in vascular smooth muscle cells via targeting miR-211/PUMA and TGF-β1/S100A4 signal. Bioengineered. 2020 Dec;11(1):718–728.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Zhang M, Zhang M, et al. Long non-coding RNA LOC285194 regulates vascular smooth muscle cell apoptosis in atherosclerosis. Bioengineered. 2020 Dec;11(1):53–60.
   PubMed Web of Science ®Google Scholar
• Diermeier-Daucher S, Clarke ST, Hill D, et al. Cell type specific applicability of 5-ethynyl-2ʹ-deoxyuridine (EdU) for dynamic proliferation assessment in flow cytometry. Cytometry A. 2009 Jun;75(6):535–546.
   PubMedGoogle Scholar
• Kim SM, Min JH, Kim JH, et al. Methyl p-hydroxycinnamate exerts anti-inflammatory effects in mouse models of lipopolysaccharide‑induced ARDS. Mol Med Rep. 2022 Jan;25(1). doi:10.3892/mmr.2021.12553.
   Web of Science ®Google Scholar
• Das PM, Ramachandran K, van Wert J, et al. Chromatin immunoprecipitation assay. BioTechniques. 2004 Dec;37(6):961–969.
   PubMed Web of Science ®Google Scholar
• Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004 Jul;84(3):767–801.
   PubMed Web of Science ®Google Scholar
• Savoia C, Burger D, Nishigaki N, et al. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med. 2011 Mar 30;13:e11.
   PubMed Web of Science ®Google Scholar
• Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007 Jan;292(1):C82–97.
   PubMed Web of Science ®Google Scholar
• Grootaert MOJ, Bennett MR. Vascular smooth muscle cells in atherosclerosis:Time for a reassessment. Cardiovasc Res. 2021 Feb 8;117:2326–2339.
   PubMed Web of Science ®Google Scholar
• Das S, Zhang E, Senapati P, et al. A novel angiotensin II-induced long noncoding RNA giver regulates oxidative stress, inflammation, and proliferation in vascular smooth muscle cells. Circ Res. 2018 Dec 7;123(12):1298–1312.
   PubMed Web of Science ®Google Scholar
• Zhao MY, Zhao T, Meng QY, et al. Estrogen and estrogen receptor affects MMP2 and MMP9 expression through classical ER pathway and promotes migration of lower venous vascular smooth muscle cells. Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1460–1467.
   PubMed Web of Science ®Google Scholar
• Shi N, Chen SY. Mechanisms simultaneously regulate smooth muscle proliferation and differentiation. J Biomed Res. 2014 Jan;28(1):40–46.
   PubMedGoogle Scholar
• Campbell GR, Campbell JH. Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. Exp Mol Pathol. 1985 Apr;42(2):139–162.
   PubMed Web of Science ®Google Scholar
• Ding Y, Zhang M, Zhang W, et al. AMP-activated protein kinase Alpha 2 deletion induces VSMC phenotypic switching and reduces features of atherosclerotic plaque stability. Circ Res. 2016 Sep 2;119(6):718–730.
   PubMed Web of Science ®Google Scholar
• Siti HN, Kamisah Y, Kamsiah J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul Pharmacol. 2015 Aug;71:40–56.
   PubMed Web of Science ®Google Scholar
• Csanyi G, Taylor WR, Pagano PJ. NOX and inflammation in the vascular adventitia. Free Radic Biol Med. 2009 Nov 1;47(9):1254–1266.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang M, Liang B, et al. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res. 2010 Apr 2;106(6):1117–1128.
   PubMed Web of Science ®Google Scholar
• Yu H, Fellows A, Foote K, et al. FOXO3a (forkhead transcription factor O subfamily member 3a) links vascular smooth muscle cell apoptosis, matrix breakdown, atherosclerosis, and vascular remodeling through a novel pathway involving MMP13 (matrix metalloproteinase 13). Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):555–565.
   PubMed Web of Science ®Google Scholar
• Lang F, Gorlach A, Vallon V. Targeting SGK1 in diabetes. Expert Opin Ther Targets. 2009 Nov;13(11):1303–1311.
   PubMed Web of Science ®Google Scholar
• Fernandez-Hernando C, Jozsef L, Jenkins D, et al. Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2033–2040.
   PubMed Web of Science ®Google Scholar
• Tucka J, Yu H, Gray K, et al. Akt1 regulates vascular smooth muscle cell apoptosis through FoxO3a and Apaf1 and protects against arterial remodeling and atherosclerosis. Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2421–2428.
   PubMed Web of Science ®Google Scholar